Latest News - AbbVie
Top Corporates Hub
AbbVie
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
22.05.2026 12:00
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C infection (HCV) in adults and children aged 3 years and older. The final European Commission decision is expected in the third quarter of 2026. If approved, MAVIRET would be indicate
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
22.05.2026 09:04
This big pharma stock checks off a lot of boxes.
Hepatic Impairment Market Analysis Report 2026-2036 Featuring AbbVie, Astellas Pharma, Gilead Sciences, F. Hoffmann La Roche, and Takeda Pharmaceuticals
21.05.2026 11:29
The hepatic impairment market is an essential segment within healthcare, focusing on managing liver conditions like hepatitis, NAFLD, and cirrhosis that impair liver function. The market is set for significant growth, driven by rising liver disease prevalence, advancements in diagnostics, and novel treatments. Trends include non-invasive diagnostics and targeted therapies, enhancing early disease management. Despite challenges like high costs and late diagnosis, opportunities lie in emerging mar
AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength
21.05.2026 08:51
AbbVie Inc. (NYSE:ABBV) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on AbbVie (NYSE: ABBV), buoyed by the company’s inflammatory bowel disease (IBD) pipeline. The research firm also raised its price target to $298 from $294, as management moves forward with Skyrizi in combination with […]
3 Stocks Estimated To Be Trading Below Intrinsic Value By 11.4% To 38.4%
20.05.2026 17:38
Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings forecasted to grow by 17% annually. In such a fluctuating environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets.
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway
20.05.2026 12:35
Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the quarter with $150.5 million in cash. The management expects the cash balance to be enough to fund operations into early 2027. Regenxbio […]
Agilysys And Two Other Stocks Priced Below Estimated Value
20.05.2026 11:38
Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings anticipated to grow by 17% annually. In this context, identifying undervalued stocks like Agilysys and others can be an effective strategy for investors seeking opportunities that are priced below their estimated value in a fluctuating market environment.
Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
19.05.2026 10:56
The polymyositis market is witnessing notable growth driven by the increasing prevalence of this autoimmune disease, particularly among older adults. Polymyositis leads to muscle inflammation and weakness, highlighting the urgency for timely diagnosis and treatment. Advancements in therapeutics, especially in biologics and immunosuppressants, are enhancing treatment efficacy. Rising disease awareness and the demand for personalized treatments are fueling market expansion. Key growth regions incl
2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts
19.05.2026 10:50
One is a well-known pharmaceutical company; the other is the king of the medical device segment.
2 Reasons to Like ABBV and 1 to Stay Skeptical
19.05.2026 08:28
Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This might have investors contemplating their next move.
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $298
14.05.2026 11:12
Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $294 to $298.
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
13.05.2026 08:15
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing
11.05.2026 08:45
AbbVie Q1 2026 beat: Skyrizi growth boosts EPS guidance. Read more here.
Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
08.05.2026 12:02
Health officials explored restricting specific antidepressants among SSRI drugs-sources
AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner
08.05.2026 11:17
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with […]
Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
07.05.2026 06:25
In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...
Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
07.05.2026 06:25
In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
06.05.2026 14:04
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
DDW 2026: key readouts from the conference
06.05.2026 12:26
Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
05.05.2026 12:05
AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) in Crohn's disease and ulcerative colitis.